NSABP Protocol B-40 - Treatment Form for Bevacizumab NCT00408408 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B7D839C-1CA0-14D8-E044-0003BA3F9857
June 16, 2015
To request one please log in.
Creative Commons BY-NC 3.0 Legacy
For treatment groups 1B, 2B, and 3B only. This form must be submitted for both the preoperative and postoperative time points.
- StudyEvent: NSABP Protocol B-40 - Treatment Form for Bevacizumab